Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
Organogenesis Holdings Inc. - Class A (ORGO)
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of ReNu®, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). “We are very pleased to have initiated our ReNu pivotal Phase 3 trial,” said Patrick Bilbo, Chief Operating Officer for Organogenesis. “This significant milestone comes on the heels of the FDA’s RMAT designation underscoring the strength of our existing ReNu clinical evidence and its potential to address a largely unmet medical need. We look forward to leveraging our RMAT designation to work closely with the FDA to expedite the review of ReNu
Show less
Read more
Impact Snapshot
Event Time:
ORGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024GlobeNewswire
- Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case [Yahoo! Finance]Yahoo! Finance
- Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud CaseGlobeNewswire
- Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Organogenesis Holdings Inc. (NASDAQ: ORGO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $5.00 price target on the stock.MarketBeat
ORGO
Earnings
- 2/29/24 - Beat
ORGO
Sec Filings
- 4/3/24 - Form 8-K
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- ORGO's page on the SEC website